Regulation & Compliance

With NHS lists at 7.4M and implants costing a year's salary, half a million Brits now fly to Türkiye for dental care. Is it a perfect solution or a risky bet?

A Dallas emergency room adopts a new name, ER of White Rock, signaling a hyper-local focus amid the complex landscape of freestanding emergency care.

New data shows first-in-class drug tegavivint successfully inhibits the Wnt pathway, a driver in 30% of solid tumors, offering hope for tough cancers.

A new platform from BEO Investments uses AI to connect disparate SEC filings, promising unprecedented transparency into who is raising and deploying capital.

Auxly Cannabis Group lost its bid for Ayurcann but secured a profitable backup role, showcasing a shrewd strategy in Canada's consolidating cannabis market.

With deep D.C. experience, Scott Dziengelski takes the helm at NABH, poised to tackle pressing issues like parity, workforce, and the addiction crisis.

VITAL MedTech unveils a bold vertical integration strategy, leveraging its parent's semiconductor mastery to build imaging systems from raw materials to final scans.

IVY Rx unveils its 2026 compounded GLP-1 program with clear pricing, but operates in a market facing intense FDA warnings and regulatory uncertainty.

Replimune halts a promising cancer therapy and cuts jobs after a stunning FDA rejection, citing a 'failed' system and inconsistent regulatory process.

A jury found Abbott's Similac caused a fatal gut disease in premature infants, igniting a legal firestorm over what the formula giant knew and when.

A Chicago jury found Abbott liable for infants' injuries from Similac, adding to a wave of lawsuits over the deadly intestinal disease NEC.

As Origin Bancorp prepares its Q1 2026 results, investors are watching for clues on regional economic health and the impact of a shifting rate environment.

Forbes named Matt Gulbransen Minnesota's #1 wealth advisor. We explore the rigorous process behind the rank and the model that builds trust with the wealthy.

Many Americans lack basic money skills, relying on friends or no one for advice. This April, experts highlight a growing crisis and the path to a solution.

A new AI parenting app, Kung Fu Family, promises personalized advice. But as it learns your child, it raises big questions about privacy and tech's role in family life.

A new state-backed tool lets Nevadans compare hospital costs, but providers warn of unintended consequences. Is this the future of healthcare transparency?

European digital health firm Apomeds launches in the UK, targeting the booming telehealth market with a focus on discreet, high-demand treatments.

A group known for challenging pandemic rules will now advise on US vaccine policy. Can it rebuild trust, or will it deepen the medical divide?

Lupin has launched a generic version of the blockbuster diabetes drug Farxiga, signaling lower costs for patients and a major shake-up in the SGLT2 market.

GEMSA and CTR launch a high-stakes exchange offer to restructure their debt, forcing a difficult choice on bondholders amid a severe financial crisis.